Lambda buys US' contract research firm Novum Pharmaceutical | Mint
Active Stocks
Fri Feb 23 2024 15:58:13
  1. Tata Steel share price
  2. 145.50 -0.24%
  1. State Bank Of India share price
  2. 759.40 -0.86%
  1. HDFC Bank share price
  2. 1,420.90 0.08%
  1. NTPC share price
  2. 337.70 -0.54%
  1. ITC share price
  2. 411.60 -0.65%
Business News/ Companies / News/  Lambda buys US' contract research firm Novum Pharmaceutical
BackBack

Lambda buys US' contract research firm Novum Pharmaceutical

Novum caters to a number of global clients through its US operations in facilities, including Pittsburgh and Las Vegas
  • Lambda, headquartered in India, has operations in India, Canada, Poland and the UK
  • The deal is by way of a private transaction (iStock)Premium
    The deal is by way of a private transaction (iStock)

    Ahmedabad: In a move to increase its presence in the US, Ahmedabad-headquartered Lambda Therapeutic Research, a leading contract research organisation (CRO) in the country, on Tuesday announced the acquisition of US-based Novum Pharmaceutical Research Services. The deal is by way of a private transaction. The terms of the deal were not disclosed.

    “This is our second footprint in North America following our acquisition of the R&D facilities of Biovail CRO in Canada in 2010. Novum is a strategic fit for Lambda as it provides a natural platform for growth in the US, the world’s largest pharmaceutical market. Novum brings with it a strong technical and management team. We expect this acquisition to blend with and strengthen our existing capabilities," Lambda managing director Bindi Chudgar said in a media release.

    Novum caters to a number of global clients through its US operations in facilities, including Pittsburgh, Las Vegas, Fargo & Houston.

    “It will be a wholly-owned subsidiary of Lambda," according to the company statement.

    Lambda, headquartered in India, has operations in India, Canada, Poland and the UK.

    “Combining with Lambda creates an opportunity for Novum and our clients to have a broader capability across the global," according to Novum CEO Christopher H. Chamberlain.

    "Our collective client base will benefit from this unique combination of companies with complimentary skills sets, a stellar track record of performance, and exceptional quality in scientific technology capabilities for complex drug product development and clinical trials. This will add greater value for our respective global clients’ drug development programmes and greater efficiencies for our combined operations," said Tausif Monif, Lambda’s president of global operations.

    BlackArch Partners served as exclusive financial adviser to Lambda Therapeutic Research on this transaction, while EY and KPMG LLC were accounting and tax advisers, respectively. Wyrick Robbins Yates & Ponton LLP were the legal advisers to Lambda. Cohen & Grigsby, P.C. in Pittsburgh, PA were the legal advisers to Novum.

    Unlock a world of Benefits! From insightful newsletters to real-time stock tracking, breaking news and a personalized newsfeed – it's all here, just a click away! Login Now!

    Catch all the Corporate news and Updates on Live Mint. Check all the latest action on Budget 2024 here. Download The Mint News App to get Daily Market Updates & Live Business News.
    More Less
    Published: 29 Jan 2019, 06:51 PM IST
    Next Story footLogo
    Recommended For You
    Switch to the Mint app for fast and personalized news - Get App